Business Context and Reporting Period
This Form 8-K Current Report was filed by Neuralstem, Inc. on September 12, 2016, regarding events occurring on September 7, 2016. The filing details a material definitive agreement and unregistered sale of equity securities involving a private placement with Tianjin Pharmaceutical Holding Group ("Tianjin").
Key Financial Metrics and Transaction Details
The filing describes a capital raise transaction rather than standard operating financial results. Key metrics include:
- Common Stock Issued: 28,500,000 shares at $0.253 per share.
- Preferred Stock Issued: 1,000,000 shares of Series A 4.5% Convertible Preferred Stock with a stated value of $12.7895 per share.
- Conversion Terms: Preferred stock is immediately convertible into 50,551,383 shares of Common Stock at $0.253 per share, subject to a 19.99% beneficial ownership limitation.
- Dilution: The Common Stock issuance represents 19.89% of outstanding shares post-issuance.
- Dividends: Series A Preferred Stock holders are entitled to 4.5% dividends in cash or additional shares, payable in preference to Common Stock.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes and Governance
The transaction results in significant changes to the company's capital structure and governance:
- Board Representation: Tianjin is entitled to appoint one member to the Board of Directors. This right terminates if fewer than 200,000 shares of Series A Preferred Stock remain outstanding.
- Voting Restrictions: Until the 2019 annual meeting, Tianjin has agreed to a standstill provision, refraining from soliciting proxies, contesting the Board, making stockholder proposals, or participating in business combinations or tender offers.
- Closing Conditions: The Offering is expected to close in the fourth quarter of 2016, contingent upon Chinese government approvals and foreign exchange transmission.
Guidance, Risks, and Contingencies
The filing highlights several risks and contingencies:
- Regulatory Approval: Closing is contingent on approvals from authorities in the People's Republic of China.
- Unregistered Securities: Securities were issued under Section 4(a)(2) of the Securities Act of 1933 and are not registered; they cannot be offered or sold in the U.S. absent registration or an exemption.
- Ownership Caps: Conversion of Preferred Stock is subject to a limitation on Tianjin's beneficial ownership of Common Stock at 19.99%.
Investor Verification Checklist
- Verify the status of the requisite government approvals in China required for the transaction to close.
- Confirm the exact closing date and the final amount of proceeds received, as the filing states the closing is expected in Q4 2016.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.01) for additional covenants or conditions not summarized in the 8-K.
- Monitor the filing of the Certificate of Designation (Exhibit 3.01) to confirm the formal establishment of Series A Preferred Stock rights.